SARS-CoV-2/COVID-19 Nucleocapsid biotinylated Antibody
Fig.1: Wells of a 96-microtiter plate were coated with 4 μg/ml of SARS-CoV-2 Nucleocapsid protein (Cat#21-1003). The binding was detected by addition of different concentration of biotinylated anti-Nucleocapsid polyclonal antibody (Cat.# 11-2003-B) per well. The reactivity was detected by HRP-conjugated Streptavidin.
Roll over image to zoom in
Order now and get it on Tuesday June 06, 2023
Same day delivery FREE on San Diego area orders placed by 1.00 PM
|Amount :||100 µg|
|Isotype :||Rabbit IgG|
|Purification :||Protein A Chromatography|
|Content :||100 µg or 25 µg in PBS with 0.05% Azide|
|Storage condition :||Store the antibody at 4°C, stable for 6 months.|
|Immunogen Information :||A partial length recombinant coronavirus Nucleocapsid protein (amino acids 250-410) was used as the immunogen for this antibody.|
The structural nucleocapsid (N) protein of nCoV/SARS-CoV-2/COVID-19 is a predicted 46 kDa phosphoprotein having 419 amino acid residues. A short Serine rich stretch and a recognized nuclear localization signal are the unique features of the nucleocapsid protein of nCoV/SARS-CoV-2/COVID-19, which seems to have a little homology with the proteins of other members of this large corona virus family. These features also suggest the involvement of nucleocapsid protein of nCoV/SARS-CoV-2/COVID-19 in different stages of viral lifecycle. The protein has multifaceted activities including packing of the nCoV/SARS-CoV-2/COVID-19 viral genome into a helical ribonucleocapsid (RNP) and playing an important role in viral self-assembly causing nCoV/SARS-CoV-2/COVID-19. The nucleocapsid protein of nCoV/SARS-CoV-2/COVID-19 also forms dimer in the cell by self-association with the help of interactive C terminal domain.
There are currently no product reviews